Sublingual immunotherapy is an alternative approach to treating allergies without using injections. It works by providing a person with small doses of what they’re allergic to, in the hopes to increase tolerance or immunity to the allergens.
Gradual increase in number of patients suffering from allergies and increasing consumers demand for minimal invasive treatment procedures are major factors expected to drive the growth of global sublingual immunotherapy market. Allergies are most common condition faced by consumers in developed and developing countries. More than 50 million Americans have experienced various types of allergies each year. In 2018, 7.7 percent of adults and 7.2 percent of children were diagnosed with hay fever. Allergies have affected people in different ways. The most common triggers for anaphylaxis, a life-threatening reaction, are medicines, food and insect stings.4 Medicines cause the most allergy related deaths. Each year in the U.S., it is estimated that anaphylaxis to food results in 30,000 emergency room visits. High investment by major players for R&D activities and inclination towards introduction of innovative solutions in order to attract new customers and enhance the business share this is expected to augment the growth of sublingual immunotherapy market.
In 2020, Cadila Pharmaceuticals Limited, a global drug manufacturing company launched Bilastine syrup (30 ml) and Bilastine tablets in the strength of 20mg. Bilastine, an antihistamine drug is used in the treatment of allergic rhinitis. The product launch is expected to help the company to enhance the business are increase the revenue share in the market.
In 2021, Glenmark Pharmaceuticals Limited, a global company engaged in R&D and manufacturing drugs launched Ryaltris®-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis in the Indian market. The product launch is expected to help the company to strengthen the share in the market and increase the product offerings.
In 2020, Dr Reddy's Laboratories, a global drugs provider launched over-the-counter (OTC) eye allergy drop Olopatadine Hydrochloride Ophthalmic Solution in the US market. The product launch is expected to help company to enhance the customer base and increase the revenue generation from US market.
Player’s inclination towards enhancing its business in developing countries with the support of favorable business policies introduced by the government of developing countries and strategic partnership are factors expected to boost the growth of sublingual immunotherapy market. Factors such as high cost associated to drug manufacturing and implication of strict regulations for drug approval are expected to hamper the growth of global sublingual immunotherapy market. In addition, lack of developed infrastructure for R&D activities is expected to challenge the growth of target market. However, rising investment by major players for R&D activities and developing medical regulatory scenario and high government spending on development of healthcare infrastructure are factors expected to create new opportunities for players operating in the sublingual immunotherapy market over the forecast period. In addition, inclination towards strategic partnership between regional and international players is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global sublingual immunotherapy market due to high patient pool suffering from chronic allergies. In addition, increasing government spending on R&D activities and high investment by payers for drug development are factors expected to augment the growth of target market. Major player’s inclination towards enhancing the business through strategic acquisitions is expected to boost the growth of sublingual immunotherapy regional market.
The global sublingual immunotherapy market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Sublingual Immunotherapy Market Segment Analysis, 2019
The global sublingual immunotherapy market is segmented into product type, distribution channel, and application. The product segment is divided into drops and tablets. Among product type the drops segment is expected to account for major revenue share in the global sublingual immunotherapy market. The players profiled in the report are Allergon AB, HAL Allergy Group, Allergy Therapeutics, Stallergenes Greer, and ALK.
Market By Product Type
Market By Distribution Channel
Retail Pharmacies and Drug Stores
Market By Application
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Gradual increase in number of patients suffering from allergies and increasing consumers demand for minimal invasive treatment procedures are major factors expected to drive the growth of global sublingual immunotherapy market.
In product type the drops segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Allergon AB, HAL Allergy Group, and Allergy Therapeutics.
The North America is expected to account for major revenue share in the global market.
Factors such as high cost associated to drug manufacturing and implication of strict regulations for drug approval are expected to hamper the growth of global sublingual immunotherapy market.